10-Q · 2026-11-09
Zentalis Pharmaceuticals announces its Q3 financial results, showcasing progress in drug development and its impact on the pharmaceutical industry.
| Name | Zentalis Pharmaceuticals, Inc. |
|---|---|
| CIK | 0001725160 |
| Tickers | ZNTL |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 823607803 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | — |
| Phone | (858) 263-4333 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Zentalis Pharmaceuticals announces its Q3 financial results, showcasing progress in drug development and its impact on the pharmaceutical industry.
Zentalis Pharmaceuticals announces Q3 2026 financial results, highlighting advancements in azenosertib for ovarian cancer and $228.9 million cash reserves.
550 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001873515-26-000003 | 005-91478 | 261562187 | 34 | 26447 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002050709-26-000033 | 005-91478 | 261558310 | 34 | 81762 | |||
| 2026-11-09 | 10-Q | 10-Q | 0001725160-26-000070 | 001-39263 | 261536065 | 34 | 6555080 | 1 | 1 | |
| 2026-11-09 | 8-K | 8-K | 2.02,7.01 | 0001725160-26-000069 | 001-39263 | 261535987 | 34 | 5148283 | 1 | 1 |
| 2026-10-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002012383-26-003868 | 005-91478 | 261491707 | 34 | 11075 | |||
| 2026-10-01 | 4 | FORM 4 | 0001628280-26-064317 | 5618 | ||||||
| 2026-08-19 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001213900-26-091824 | 005-91478 | 261296692 | 34 | 10479 | |||
| 2026-08-19 | 4 | xslF345X06/ownership.xml | 0001213900-26-091823 | 9185 | ||||||
| 2026-08-14 | 8-K | 8-K | 8.01,9.01 | 0001628280-26-057112 | 001-39263 | 261281535 | 34 | 453247 | 1 | 1 |
| 2026-08-14 | 424B5 | 424B5 | 0001628280-26-057108 | 333-286122 | 261281503 | 33 | 573497 | |||
| 2026-08-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000312069-26-000217 | 005-91478 | 261275518 | 34 | 6503 | |||
| 2026-08-13 | 424B5 | 424B5 | 0001628280-26-056729 | 333-286122 | 261273539 | 33 | 603221 | |||
| 2026-08-06 | 10-Q | 10-Q | 0001725160-26-000062 | 001-39263 | 261249200 | 34 | 6414993 | 1 | 1 | |
| 2026-08-06 | 8-K | 8-K | 2.02,7.01 | 0001725160-26-000061 | 001-39263 | 261249086 | 34 | 5930844 | 1 | 1 |
| 2026-07-30 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002012383-26-003135 | 005-91478 | 261221135 | 34 | 11023 | |||
| 2026-06-18 | 4 | FORM 4 | 0001808098-26-000003 | 318265 | ||||||
| 2026-06-18 | 4 | FORM 4 | 0001838042-26-000003 | 313499 | ||||||
| 2026-06-18 | 4 | FORM 4 | 0001701440-26-000004 | 345162 | ||||||
| 2026-06-18 | 4 | FORM 4 | 0001843119-26-000003 | 319860 | ||||||
| 2026-06-18 | 4 | FORM 4 | 0001356256-26-000005 | 318266 | ||||||
| 2026-06-18 | 8-K | 8-K | 5.07 | 0001725160-26-000052 | 001-39263 | 261102436 | 34 | 177995 | 1 | 1 |
| 2026-05-27 | 4 | FORM 4 | 0002018966-26-000005 | 5295 | ||||||
| 2026-05-27 | 3 | FORM 3 | 0002018966-26-000004 | 343623 | ||||||
| 2026-05-27 | DEFA14A | DEFA14A | 0001725160-26-000050 | 001-39263 | 261026203 | 34 | 653879 | |||
| 2026-05-27 | 8-K | 8-K | 5.02 | 0001725160-26-000049 | 001-39263 | 261026183 | 34 | 163045 | 1 | 1 |
| 2026-05-21 | 8-K | 8-K | 7.01,8.01 | 0001725160-26-000045 | 001-39263 | 261010026 | 34 | 381981 | 1 | 1 |
| 2026-05-12 | 10-Q | 10-Q | 0001725160-26-000042 | 001-39263 | 26968639 | 34 | 5929020 | 1 | 1 | |
| 2026-05-12 | 8-K | 8-K | 2.02,7.01 | 0001725160-26-000041 | 001-39263 | 26968568 | 34 | 5928923 | 1 | 1 |
| 2026-05-05 | 8-K | 8-K | 7.01,8.01 | 0001725160-26-000033 | 001-39263 | 26940514 | 34 | 296774 | 1 | 1 |
| 2026-04-30 | DEFA14A | DEFA14A | 0001725160-26-000028 | 001-39263 | 26925329 | 34 | 1256976 | |||
| 2026-04-30 | DEF 14A | DEF 14A | 0001725160-26-000027 | 001-39263 | 26925099 | 34 | 3691532 | 1 | 1 | |
| 2026-04-30 | ARS | ARS | 0001725160-26-000026 | 001-39263 | 26924932 | 34 | 20597548 | |||
| 2026-04-17 | 8-K | 8-K | 7.01 | 0001725160-26-000020 | 001-39263 | 26871172 | 34 | 8698773 | 1 | 1 |
| 2026-04-09 | 8-K | 8-K | 7.01,8.01 | 0001725160-26-000017 | 001-39263 | 26849864 | 34 | 6764114 | 1 | 1 |
| 2026-03-26 | 10-K | 10-K | 0001725160-26-000014 | 001-39263 | 26799017 | 34 | 10446795 | 1 | 1 | |
| 2026-03-26 | 8-K | 8-K | 2.02,9.01 | 0001725160-26-000010 | 001-39263 | 26798608 | 34 | 354062 | 1 | 1 |
| 2026-03-03 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002050709-26-000011 | 005-91478 | 26713930 | 34 | 80885 | |||
| 2026-02-10 | 4 | FORM 4 | 0001838041-26-000004 | 6467 | ||||||
| 2026-02-10 | 4 | FORM 4 | 0002018766-26-000006 | 8044 | ||||||
| 2026-02-10 | 4 | FORM 4 | 0001500189-26-000004 | 6503 | ||||||
| 2026-02-04 | 4 | FORM 4 | 0002018766-26-000004 | 6622 | ||||||
| 2026-01-09 | 4 | FORM 4 | 0002018766-26-000002 | 315325 | ||||||
| 2026-01-09 | 4 | FORM 4 | 0001664928-26-000003 | 5581 | ||||||
| 2026-01-09 | 4 | FORM 4 | 0001838041-26-000002 | 314559 | ||||||
| 2026-01-09 | 4 | FORM 4 | 0001500189-26-000002 | 313104 | ||||||
| 2026-01-09 | 8-K | 8-K | 7.01,8.01 | 0001725160-26-000003 | 001-39263 | 26523980 | 34 | 6771976 | 1 | 1 |
| 2026-01-08 | 4 | xslF345X05/ownership.xml | 0001213900-26-002567 | 8926 | ||||||
| 2026-01-08 | 3 | OWNERSHIP DOCUMENT | 0001213900-26-002566 | 8739 | ||||||
| 2026-01-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001213900-26-001456 | 005-91478 | 26509092 | 34 | 11142 | |||
| 2026-01-02 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0000902664-26-000024 | 005-91478 | 26502478 | 34 | 9706 | |||
| 2025-12-30 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001873515-25-000004 | 005-91478 | 251614379 | 34 | 22591 | |||
| 2025-12-15 | 4 | xslF345X05/ownership.xml | 0000902664-25-005288 | 7940 | ||||||
| 2025-12-15 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0000902664-25-005287 | 005-91478 | 251572501 | 34 | 10101 | |||
| 2025-12-15 | 8-K | 8-K | 5.02,8.01 | 0001725160-25-000164 | 001-39263 | 251572355 | 34 | 170605 | 1 | 1 |
| 2025-11-12 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000312069-25-000592 | 005-91478 | 251472663 | 34 | 6378 | |||
| 2025-11-10 | 10-Q | 10-Q | 0001725160-25-000161 | 001-39263 | 251466400 | 34 | 6988150 | 1 | 1 | |
| 2025-11-10 | 8-K | 8-K | 2.02,7.01,9.01 | 0001725160-25-000159 | 001-39263 | 251466290 | 34 | 6657710 | 1 | 1 |
| 2025-10-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-099251 | 005-91478 | 251391679 | 34 | 15771 | |||
| 2025-10-01 | 4 | FORM 4 | 0001664928-25-000008 | 5690 | ||||||
| 2025-09-22 | 3 | FORM 3 | 0001664928-25-000006 | 321643 | ||||||
| 2025-08-26 | 8-K | 8-K | 5.02,7.01,9.01 | 0001725160-25-000154 | 001-39263 | 251257671 | 34 | 284110 | 1 | 1 |
| 2025-08-06 | 10-Q | 10-Q | 0001725160-25-000149 | 001-39263 | 251189732 | 34 | 6995609 | 1 | 1 | |
| 2025-08-06 | 8-K | 8-K | 2.02,7.01 | 0001725160-25-000147 | 001-39263 | 251189590 | 34 | 6648942 | 1 | 1 |
| 2025-07-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-002526 | 005-91478 | 251128504 | 34 | 11029 | |||
| 2025-06-18 | 4 | FORM 4 | 0001725160-25-000137 | 5258 | ||||||
| 2025-06-18 | 4 | FORM 4 | 0001725160-25-000135 | 5231 | ||||||
| 2025-06-18 | 4 | FORM 4 | 0001725160-25-000133 | 5267 | ||||||
| 2025-06-18 | 4 | FORM 4 | 0001725160-25-000131 | 5248 | ||||||
| 2025-06-18 | 4 | FORM 4 | 0001725160-25-000129 | 5254 | ||||||
| 2025-06-18 | 8-K | 8-K | 5.07 | 0001725160-25-000127 | 001-39263 | 251056994 | 34 | 180462 | 1 | 1 |
| 2025-06-02 | 8-K | 8-K | 7.01,9.01 | 0001725160-25-000119 | 001-39263 | 251012990 | 34 | 3840660 | 1 | 1 |
| 2025-05-23 | DEFA14A | DEFA14A | 0001725160-25-000112 | 001-39263 | 25982603 | 34 | 39263 | |||
| 2025-05-20 | 8-K | 8-K | 7.01,9.01 | 0001725160-25-000108 | 001-39263 | 25966063 | 34 | 163174 | 1 | 1 |
| 2025-05-14 | S-8 | S-8 | 0001725160-25-000106 | 333-287263 | 25945756 | 33 | 376929 | |||
| 2025-05-14 | 10-Q | 10-Q | 0001725160-25-000105 | 001-39263 | 25945644 | 34 | 6816342 | 1 | 1 | |
| 2025-05-14 | 8-K | 8-K | 2.02,9.01 | 0001725160-25-000104 | 001-39263 | 25945521 | 34 | 344648 | 1 | 1 |
| 2025-05-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001580642-25-003116 | 005-91478 | 25944993 | 34 | 11413 | |||
| 2025-05-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001580642-25-003101 | 005-91478 | 25941681 | 34 | 11366 | |||
| 2025-04-30 | 4 | FORM 4 | 0001725160-25-000094 | 4733 | ||||||
| 2025-04-30 | DEFA14A | DEFA14A | 0001725160-25-000093 | 001-39263 | 25895373 | 34 | 1241911 | |||
| 2025-04-30 | DEF 14A | DEF 14A | 0001725160-25-000092 | 001-39263 | 25895150 | 34 | 3388969 | 1 | 1 | |
| 2025-04-30 | ARS | ARS | 0001725160-25-000091 | 001-39263 | 25894906 | 34 | 21103616 | |||
| 2025-04-28 | 8-K | 8-K | 7.01,9.01 | 0001725160-25-000082 | 001-39263 | 25875818 | 34 | 15655351 | 1 | 1 |
| 2025-04-04 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-000989 | 333-286122 | 25816231 | 33 | 1953 | ||
| 2025-04-02 | CORRESP | filename1.htm | 0001725160-25-000073 | 10482 | ||||||
| 2025-04-01 | UPLOAD | filename1.pdf | 0000000000-25-003491 | 333-286122 | 40344 | |||||
| 2025-03-26 | 8-K | 8-K | 2.02,9.01 | 0001725160-25-000070 | 001-39263 | 25773552 | 34 | 355175 | 1 | 1 |
| 2025-03-26 | S-3 | S-3 | 0001725160-25-000069 | 333-286122 | 25773519 | 33 | 1445869 | |||
| 2025-03-26 | 10-K | 10-K | 0001725160-25-000067 | 001-39263 | 25773286 | 34 | 11591632 | 1 | 1 | |
| 2025-03-17 | 8-K | 8-K | 7.01,9.01 | 0001628280-25-012899 | 001-39263 | 25742266 | 34 | 2484330 | 1 | 1 |
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001580642-25-001015 | 005-91478 | 25625554 | 34 | 15231 | |||
| 2025-02-12 | 4 | FORM 4 | 0001725160-25-000047 | 4782 | ||||||
| 2025-02-11 | 144 | xsl144X01/primary_doc.xml | 0001725160-25-000045 | 001-39263 | 25611511 | 33 | 5434 | |||
| 2025-02-05 | 4 | FORM 4 | 0001725160-25-000043 | 9066 | ||||||
| 2025-02-05 | 4 | FORM 4 | 0001725160-25-000041 | 9066 | ||||||
| 2025-02-05 | 4 | FORM 4 | 0001725160-25-000040 | 8982 | ||||||
| 2025-02-05 | 4 | FORM 4 | 0001725160-25-000037 | 7395 | ||||||
| 2025-02-05 | 4 | FORM 4 | 0001725160-25-000036 | 7424 | ||||||
| 2025-02-04 | 4 | FORM 4 | 0001725160-25-000030 | 4706 | ||||||
| 2025-02-04 | 4 | FORM 4 | 0001725160-25-000029 | 4743 | ||||||
| 2025-02-04 | 4 | FORM 4 | 0001725160-25-000028 | 4811 | ||||||
| 2025-02-04 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-009101 | 005-91478 | 25588150 | 34 | 15142 | |||
| 2025-02-03 | 144 | xsl144X01/primary_doc.xml | 0001725160-25-000022 | 001-39263 | 25584318 | 33 | 5297 | |||
| 2025-02-03 | 144 | xsl144X01/primary_doc.xml | 0001725160-25-000020 | 001-39263 | 25584313 | 33 | 4628 | |||
| 2025-02-03 | 144 | xsl144X01/primary_doc.xml | 0001725160-25-000018 | 001-39263 | 25584312 | 33 | 4941 | |||
| 2025-01-31 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002053359-25-000002 | 005-91478 | 25577181 | 34 | 9519 | |||
| 2025-01-31 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000932471-25-000275 | 005-91478 | 25576429 | 34 | 6469 | |||
| 2025-01-29 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-25-000013 | 001-39263 | 25566983 | 34 | 7552538 | 1 | 1 |
| 2025-01-28 | 8-K | 8-K | 2.05,7.01,8.01,9.01 | 0001725160-25-000006 | 001-39263 | 25564187 | 34 | 302042 | 1 | 1 |
| 2025-01-22 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001689655-25-000004 | 005-91478 | 25544147 | 34 | 9501 | |||
| 2025-01-08 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001689655-25-000001 | 005-91478 | 25519644 | 34 | 9531 | |||
| 2025-01-03 | 4 | FORM 4 | 0001725160-25-000002 | 5081 | ||||||
| 2024-12-19 | 8-K/A | 8-K/A | 5.02 | 0001725160-24-000193 | 001-39263 | 241563261 | 34 | 177169 | 1 | 1 |
| 2024-12-10 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001689655-24-000020 | 005-91478 | 241537756 | 34 | 9419 | |||
| 2024-12-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-24-002990 | 005-91478 | 241531243 | 34 | 11592 | |||
| 2024-12-03 | 4 | FORM 4 | 0001725160-24-000190 | 5771 | ||||||
| 2024-12-03 | 4 | FORM 4 | 0001725160-24-000189 | 5760 | ||||||
| 2024-11-14 | SC 13G/A | SC 13G/A | 0001104659-24-118978 | 005-91478 | 241462753 | 34 | 136915 | |||
| 2024-11-13 | 4 | FORM 4 | 0001725160-24-000186 | 5157 | ||||||
| 2024-11-13 | 3 | FORM 3 | 0001725160-24-000185 | 342463 | ||||||
| 2024-11-13 | 3 | FORM 3 | 0001725160-24-000184 | 343046 | ||||||
| 2024-11-13 | 3 | FORM 3 | 0001725160-24-000183 | 341595 | ||||||
| 2024-11-13 | 8-K | 8-K | 5.02,7.01,9.01 | 0001725160-24-000177 | 001-39263 | 241451278 | 34 | 235437 | 1 | 1 |
| 2024-11-12 | SC 13G/A | UnitedStates_13G__ZentalisPh.txt | 0000932471-24-001300 | 005-91478 | 241450347 | 34 | 6771 | |||
| 2024-11-12 | 10-Q | 10-Q | 0001725160-24-000173 | 001-39263 | 241447722 | 34 | 11267560 | 1 | 1 | |
| 2024-11-06 | SC 13G/A | SC 13G/A | 0001580642-24-006742 | 005-91478 | 241430345 | 34 | 57746 | |||
| 2024-11-04 | SC 13G/A | UnitedStates_13G__ZentalisPh.txt | 0000932471-24-000785 | 005-91478 | 241422622 | 34 | 5808 | |||
| 2024-10-31 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000168 | 001-39263 | 241416728 | 33 | 4613 | |||
| 2024-10-18 | SC 13G/A | Zentalis_Pharma_Inc.htm | 0000093751-24-000899 | 005-91478 | 241379776 | 34 | 56063 | |||
| 2024-10-17 | UPLOAD | filename1.pdf | 0000000000-24-011665 | 001-39263 | 39920 | |||||
| 2024-10-10 | CORRESP | filename1.htm | 0001725160-24-000166 | 126011 | ||||||
| 2024-10-07 | SC 13G/A | filing.txt | 0000315066-24-002028 | 005-91478 | 241356669 | 34 | 8478 | |||
| 2024-10-04 | 4 | FORM 4 | 0001725160-24-000163 | 5160 | ||||||
| 2024-09-16 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-24-000161 | 001-39263 | 241299302 | 34 | 290208 | 1 | 1 |
| 2024-09-12 | UPLOAD | filename1.pdf | 0000000000-24-010304 | 001-39263 | 44144 | |||||
| 2024-08-09 | 10-Q | 10-Q | 0001725160-24-000158 | 001-39263 | 241190377 | 34 | 11591161 | 1 | 1 | |
| 2024-08-09 | 8-K | 8-K | 2.02,9.01 | 0001725160-24-000157 | 001-39263 | 241190371 | 34 | 344470 | 1 | 1 |
| 2024-06-21 | 4 | FORM 4 | 0001725160-24-000145 | 354520 | ||||||
| 2024-06-21 | 4 | FORM 4 | 0001725160-24-000143 | 355357 | ||||||
| 2024-06-21 | 4 | FORM 4 | 0001725160-24-000141 | 349922 | ||||||
| 2024-06-21 | 8-K | 8-K | 5.07 | 0001725160-24-000140 | 001-39263 | 241061311 | 34 | 188893 | 1 | 1 |
| 2024-06-03 | 8-K | 8-K | 7.01,9.01 | 0001725160-24-000131 | 001-39263 | 241011960 | 34 | 9376151 | 1 | 1 |
| 2024-05-31 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000129 | 001-39263 | 241011392 | 33 | 4871 | |||
| 2024-05-31 | 4 | FORM 4 | 0001725160-24-000127 | 327961 | ||||||
| 2024-05-29 | 4 | FORM 4 | 0001725160-24-000123 | 5092 | ||||||
| 2024-05-29 | 3 | FORM 3 | 0001725160-24-000122 | 329016 | ||||||
| 2024-05-29 | DEFA14A | DEFA14A | 0001725160-24-000121 | 001-39263 | 24994005 | 34 | 131015 | |||
| 2024-05-29 | 8-K | 8-K | 5.02 | 0001725160-24-000120 | 001-39263 | 24993988 | 34 | 159673 | 1 | 1 |
| 2024-05-09 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000113 | 001-39263 | 24932517 | 33 | 4650 | |||
| 2024-05-09 | 4 | FORM 4 | 0001725160-24-000111 | 355217 | ||||||
| 2024-05-07 | 10-Q | 10-Q | 0001725160-24-000107 | 001-39263 | 24919562 | 34 | 6535156 | 1 | 1 | |
| 2024-05-07 | 8-K | 8-K | 2.02,9.01 | 0001725160-24-000106 | 001-39263 | 24919550 | 34 | 355096 | 1 | 1 |
| 2024-04-29 | DEFA14A | DEFA14A | 0001725160-24-000097 | 001-39263 | 24891777 | 34 | 1234026 | |||
| 2024-04-29 | DEF 14A | DEF 14A | 0001725160-24-000096 | 001-39263 | 24891640 | 34 | 5201838 | 1 | 1 | |
| 2024-04-29 | ARS | ARS | 0001725160-24-000095 | 001-39263 | 24891522 | 34 | 22478354 | |||
| 2024-04-11 | 3 | FORM 3 | 0001725160-24-000089 | 350621 | ||||||
| 2024-04-11 | 8-K | 8-K | 5.02 | 0001725160-24-000087 | 001-39263 | 24837104 | 34 | 163565 | 1 | 1 |
| 2024-04-09 | 8-K | 8-K | 7.01,9.01 | 0001725160-24-000082 | 001-39263 | 24833109 | 34 | 8458035 | 1 | 1 |
| 2024-02-29 | S-8 | S-8 | 0001628280-24-008062 | 333-277550 | 24705180 | 33 | 377097 | |||
| 2024-02-29 | S-3ASR | S-3ASR | 0001628280-24-008056 | 333-277545 | 24705089 | 33 | 1432861 | |||
| 2024-02-27 | 10-K | 10-K | 0001725160-24-000080 | 001-39263 | 24681940 | 34 | 49627536 | 1 | 1 | |
| 2024-02-27 | 8-K | 8-K | 2.02,9.01 | 0001725160-24-000079 | 001-39263 | 24681923 | 34 | 363276 | 1 | 1 |
| 2024-02-15 | 8-K | 8-K | 5.03,9.01 | 0001725160-24-000057 | 001-39263 | 24643942 | 34 | 529112 | 1 | 1 |
| 2024-02-14 | SC 13G/A | SC 13G/A | 0001104659-24-023930 | 005-91478 | 24639965 | 34 | 138021 | |||
| 2024-02-13 | SC 13G/A | d10977822_13g-a.htm | 0000919574-24-001194 | 005-91478 | 24631207 | 34 | 162610 | |||
| 2024-02-13 | SC 13G/A | SCHEDULE 13G/A | 0001104659-24-022352 | 005-91478 | 24629970 | 34 | 13240 | |||
| 2024-02-12 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000049 | 001-39263 | 24622206 | 33 | 5447 | |||
| 2024-02-12 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000047 | 001-39263 | 24622205 | 33 | 5410 | |||
| 2024-02-12 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000045 | 001-39263 | 24622203 | 33 | 5460 | |||
| 2024-02-12 | 4 | FORM 4 | 0001725160-24-000043 | 5481 | ||||||
| 2024-02-12 | 4 | FORM 4 | 0001725160-24-000041 | 5461 | ||||||
| 2024-02-09 | SC 13G/A | SEC SCHEDULE 13G | 0001422848-24-000149 | 005-91478 | 24616631 | 34 | 18594 | |||
| 2024-02-09 | SC 13G/A | filing.txt | 0000315066-24-001568 | 005-91478 | 24612622 | 34 | 8425 | |||
| 2024-02-09 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-24-000276 | 005-91478 | 24611404 | 34 | 33142 | |||
| 2024-02-05 | 4 | FORM 4 | 0001725160-24-000036 | 7839 | ||||||
| 2024-02-05 | 4 | FORM 4 | 0001725160-24-000034 | 9645 | ||||||
| 2024-02-05 | 4 | FORM 4 | 0001725160-24-000032 | 11935 | ||||||
| 2024-02-05 | 4 | FORM 4 | 0001725160-24-000030 | 9428 | ||||||
| 2024-02-05 | 4 | FORM 4 | 0001725160-24-000028 | 9443 | ||||||
| 2024-02-05 | 4 | FORM 4 | 0001725160-24-000026 | 8948 | ||||||
| 2024-02-02 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000024 | 001-39263 | 24593709 | 33 | 4623 | |||
| 2024-02-02 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000023 | 001-39263 | 24593708 | 33 | 4558 | |||
| 2024-02-02 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000022 | 001-39263 | 24593706 | 33 | 4804 | |||
| 2024-02-02 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000021 | 001-39263 | 24593704 | 33 | 4839 | |||
| 2024-02-02 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000020 | 001-39263 | 24593703 | 33 | 4801 | |||
| 2024-02-02 | 144 | xsl144X01/primary_doc.xml | 0001725160-24-000019 | 001-39263 | 24593701 | 33 | 4852 | |||
| 2024-01-29 | SC 13G/A | us98943l1070_012924.txt | 0001086364-24-005115 | 005-91478 | 24573094 | 34 | 13745 | |||
| 2024-01-25 | SC 13G/A | Zentalis_Pharma_Inc.txt | 0000093751-24-000199 | 005-91478 | 24558601 | 34 | 8664 | |||
| 2024-01-25 | 8-K | 8-K | 3.01,5.02,7.01,9.01 | 0001725160-24-000012 | 001-39263 | 24558556 | 34 | 218109 | 1 | 1 |
| 2024-01-08 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-24-000007 | 001-39263 | 24518285 | 34 | 228654 | 1 | 1 |
| 2024-01-03 | 4 | FORM 4 | 0001725160-24-000004 | 7771 | ||||||
| 2024-01-03 | 3 | FORM 3 | 0001725160-24-000003 | 224622 | ||||||
| 2023-12-21 | 4 | FORM 4 | 0001725160-23-000203 | 7048 | ||||||
| 2023-12-11 | SC 13G/A | SC 13G/A | 0001580642-23-006644 | 005-91478 | 231478945 | 34 | 57430 | |||
| 2023-11-17 | SC 13G | SC 13G | 0001104659-23-119603 | 005-91478 | 231419878 | 34 | 142920 | |||
| 2023-11-13 | 4 | FORM 4 | 0001725160-23-000201 | 5094 | ||||||
| 2023-11-13 | 4 | FORM 4 | 0001725160-23-000200 | 4678 | ||||||
| 2023-11-06 | 10-Q | 10-Q | 0001725160-23-000196 | 001-39263 | 231378608 | 34 | 7122232 | 1 | 1 | |
| 2023-11-06 | 8-K | 8-K | 2.02,7.01,9.01 | 0001725160-23-000195 | 001-39263 | 231378601 | 34 | 8820346 | 1 | 1 |
| 2023-10-10 | SC 13G | SC 13G | 0001580642-23-005465 | 005-91478 | 231317800 | 34 | 59764 | |||
| 2023-10-06 | 4 | FORM 4 | 0001725160-23-000181 | 7265 | ||||||
| 2023-10-06 | 4 | FORM 4 | 0001725160-23-000180 | 9260 | ||||||
| 2023-10-06 | 4 | FORM 4 | 0001725160-23-000179 | 7516 | ||||||
| 2023-10-06 | 8-K | 8-K | 5.02 | 0001725160-23-000178 | 001-39263 | 231314798 | 34 | 158742 | 1 | 1 |
| 2023-10-04 | 144 | xsl144X01/primary_doc.xml | 0001725160-23-000172 | 001-39263 | 231309566 | 33 | 5088 | |||
| 2023-10-04 | 144 | xsl144X01/primary_doc.xml | 0001725160-23-000170 | 001-39263 | 231309561 | 33 | 5118 | |||
| 2023-10-04 | 144 | xsl144X01/primary_doc.xml | 0001725160-23-000168 | 001-39263 | 231309557 | 33 | 5089 | |||
| 2023-09-13 | 4 | FORM 4 | 0001725160-23-000162 | 5249 | ||||||
| 2023-09-13 | 8-K | 8-K | 7.01,9.01 | 0001725160-23-000161 | 001-39263 | 231251588 | 34 | 6844418 | 1 | 1 |
| 2023-09-11 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-003872 | 001-39263 | 231247824 | 33 | 4826 | |||
| 2023-08-09 | 8-K | 8-K | 7.01,9.01 | 0001725160-23-000157 | 001-39263 | 231155344 | 34 | 7440708 | 1 | 1 |
| 2023-08-09 | 10-Q | 10-Q | 0001725160-23-000155 | 001-39263 | 231153332 | 34 | 7370977 | 1 | 1 | |
| 2023-08-09 | 8-K | 8-K | 2.02,9.01 | 0001725160-23-000154 | 001-39263 | 231153317 | 34 | 323772 | 1 | 1 |
| 2023-06-20 | 4 | xslF345X04/ownership.xml | 0000902664-23-003642 | 7728 | ||||||
| 2023-06-20 | SC 13D/A | ZENTALIS PHARMACEUTICALS, INC. | 0000902664-23-003640 | 005-91478 | 231025567 | 34 | 51294 | |||
| 2023-06-16 | 8-K | 8-K | 5.03,5.07,9.01 | 0001725160-23-000148 | 001-39263 | 231022306 | 34 | 216378 | 1 | 1 |
| 2023-06-16 | 4 | FORM 4 | 0001725160-23-000146 | 5133 | ||||||
| 2023-06-16 | 4 | FORM 4 | 0001725160-23-000143 | 5113 | ||||||
| 2023-06-16 | 4 | FORM 4 | 0001725160-23-000141 | 5096 | ||||||
| 2023-06-15 | 8-K | 8-K | 8.01,9.01 | 0001628280-23-022240 | 001-39263 | 231017674 | 34 | 557463 | 1 | 1 |
| 2023-06-15 | 424B5 | 424B5 | 0001628280-23-022224 | 333-255769 | 231017465 | 33 | 585378 | |||
| 2023-06-15 | FWP | FWP | 0001628280-23-022129 | 333-255769 | 231015938 | 34 | 134206 | |||
| 2023-06-15 | 8-K | 8-K | 8.01 | 0001725160-23-000137 | 001-39263 | 231015880 | 34 | 178784 | 1 | 1 |
| 2023-06-06 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-23-000131 | 001-39263 | 23995036 | 34 | 15849385 | 1 | 1 |
| 2023-06-05 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-23-000129 | 001-39263 | 23992035 | 34 | 920530 | 1 | 1 |
| 2023-05-31 | 144 | xsl144X01/primary_doc.xml | 0001725160-23-000126 | 001-39263 | 23982859 | 33 | 5146 | |||
| 2023-05-31 | 4 | FORM 4 | 0001725160-23-000125 | 6945 | ||||||
| 2023-05-31 | 4 | FORM 4 | 0001725160-23-000124 | 7296 | ||||||
| 2023-05-31 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-001083 | 001-39263 | 23981495 | 33 | 4883 | |||
| 2023-05-26 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-23-000119 | 001-39263 | 23966142 | 34 | 263405 | 1 | 1 |
| 2023-05-10 | 4 | FORM 4 | 0001725160-23-000116 | 5152 | ||||||
| 2023-05-10 | 3 | FORM 3 | 0001725160-23-000115 | 479906 | ||||||
| 2023-05-10 | DEFA14A | DEFA14A | 0001725160-23-000114 | 001-39263 | 23904302 | 34 | 76267 | |||
| 2023-05-10 | 10-Q | 10-Q | 0001725160-23-000113 | 001-39263 | 23904295 | 34 | 6463594 | 1 | 1 | |
| 2023-05-10 | 8-K | 8-K | 2.02,9.01 | 0001725160-23-000112 | 001-39263 | 23904287 | 34 | 264795 | 1 | 1 |
| 2023-04-28 | DEFA14A | DEFA14A | 0001725160-23-000082 | 001-39263 | 23867338 | 34 | 1299584 | |||
| 2023-04-28 | ARS | ARS | 0001725160-23-000080 | 001-39263 | 23867314 | 34 | 2433713 | |||
| 2023-04-28 | DEF 14A | DEF 14A | 0001725160-23-000078 | 001-39263 | 23867210 | 34 | 3559214 | 1 | 1 | |
| 2023-04-26 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-23-000073 | 001-39263 | 23850621 | 34 | 247974 | 1 | 1 |
| 2023-04-18 | PRE 14A | PRE 14A | 0001725160-23-000068 | 001-39263 | 23827187 | 34 | 3483167 | 1 | 1 | |
| 2023-04-17 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-23-000063 | 001-39263 | 23823006 | 34 | 8627678 | 1 | 1 |
| 2023-03-10 | 8-K | 8-K | 7.01 | 0001725160-23-000057 | 001-39263 | 23724184 | 34 | 179921 | 1 | 1 |
| 2023-03-10 | SC 13G/A | SC 13G/A | 0001104659-23-030717 | 005-91478 | 23721239 | 34 | 31060 | |||
| 2023-03-09 | 8-K | 8-K | 1.01 | 0001725160-23-000053 | 001-39263 | 23720336 | 34 | 180441 | 1 | 1 |
| 2023-03-02 | 4 | FORM 4 | 0001725160-23-000050 | 7369 | ||||||
| 2023-03-01 | 10-K | 10-K | 0001725160-23-000048 | 001-39263 | 23689690 | 34 | 12386155 | 1 | 1 | |
| 2023-03-01 | 8-K | 8-K | 2.02,7.01 | 0001725160-23-000047 | 001-39263 | 23689680 | 34 | 8320549 | 1 | 1 |
| 2023-02-14 | 4 | FORM 4 | 0001725160-23-000035 | 7444 | ||||||
| 2023-02-14 | 4 | FORM 4 | 0001725160-23-000033 | 7425 | ||||||
| 2023-02-14 | 4 | FORM 4 | 0001725160-23-000031 | 9432 | ||||||
| 2023-02-14 | SC 13G/A | zntl13gadec22.txt | 0000080255-23-002712 | 005-91478 | 34 | 7202 | ||||
| 2023-02-14 | SC 13G/A | d9942383_13g-a.htm | 0000919574-23-001460 | 005-91478 | 23625207 | 34 | 166771 | |||
| 2023-02-14 | SC 13G | sch13ga.htm | 0000929638-23-000483 | 005-91478 | 23624360 | 34 | 99906 | |||
| 2023-02-13 | SC 13G | SEC SCHEDULE 13G | 0001562230-23-000093 | 005-91478 | 23618029 | 34 | 18517 | |||
| 2023-02-13 | 3 | FORM 3 | 0001725160-23-000029 | 496641 | ||||||
| 2023-02-13 | 8-K | 8-K | 5.02,9.01 | 0001725160-23-000028 | 001-39263 | 23614644 | 34 | 7788451 | 1 | 1 |
| 2023-02-09 | SC 13G/A | filing.txt | 0000315066-23-002153 | 005-91478 | 23605175 | 34 | 8338 | |||
| 2023-02-09 | SC 13G/A | SCHEDULE 13G/A | 0001104659-23-017354 | 005-91478 | 23604636 | 34 | 13133 | |||
| 2023-02-07 | SC 13G | Zentalis_Pharma_Inc.txt | 0000093751-23-000312 | 005-91478 | 23593932 | 34 | 8599 | |||
| 2023-02-06 | 4 | FORM 4 | 0001725160-23-000022 | 7168 | ||||||
| 2023-02-06 | SC 13G | SEC SCHEDULE 13G | 0000846087-23-000198 | 005-91478 | 23590250 | 34 | 37641 | |||
| 2023-02-01 | 4 | FORM 4 | 0001725160-23-000020 | 10584 | ||||||
| 2023-02-01 | 4 | FORM 4 | 0001725160-23-000019 | 7112 | ||||||
| 2023-02-01 | 4 | FORM 4 | 0001725160-23-000018 | 7168 | ||||||
| 2023-02-01 | 4 | FORM 4 | 0001725160-23-000017 | 7330 | ||||||
| 2023-02-01 | 4 | FORM 4 | 0001725160-23-000016 | 7052 | ||||||
| 2023-02-01 | 4 | FORM 4 | 0001725160-23-000015 | 7107 | ||||||
| 2023-02-01 | SC 13G/A | us98943l1070_020123.txt | 0001306550-23-006402 | 005-91478 | 23577614 | 34 | 13523 | |||
| 2023-01-18 | 4 | FORM 4 | 0001725160-23-000008 | 7168 | ||||||
| 2023-01-09 | 8-K | 8-K | 7.01,9.01 | 0001725160-23-000006 | 001-39263 | 23516495 | 34 | 8800095 | 1 | 1 |
| 2023-01-05 | 4 | FORM 4 | 0001725160-23-000002 | 7168 | ||||||
| 2022-11-15 | 4 | FORM 4 | 0001725160-22-000202 | 7167 | ||||||
| 2022-11-09 | 10-Q | 10-Q | 0001725160-22-000200 | 001-39263 | 221370629 | 34 | 7120198 | 1 | 1 | |
| 2022-11-09 | 8-K | 8-K | 2.02,7.01 | 0001725160-22-000199 | 001-39263 | 221370613 | 34 | 8706896 | 1 | 1 |
| 2022-11-08 | 4 | FORM 4 | 0001725160-22-000194 | 9040 | ||||||
| 2022-10-31 | 10-K/A | 10-K/A | 0001725160-22-000187 | 001-39263 | 221347224 | 34 | 341223 | 1 | 1 | |
| 2022-10-17 | 4 | FORM 4 | 0001725160-22-000184 | 5302 | ||||||
| 2022-10-07 | 4 | FORM 4 | 0001725160-22-000182 | 9039 | ||||||
| 2022-10-03 | 4 | FORM 4 | 0001725160-22-000180 | 5260 | ||||||
| 2022-10-03 | 4 | FORM 4 | 0001725160-22-000179 | 9469 | ||||||
| 2022-10-03 | 4 | FORM 4 | 0001725160-22-000178 | 10166 | ||||||
| 2022-10-03 | 3 | FORM 3 | 0001725160-22-000177 | 498952 | ||||||
| 2022-09-27 | 8-K | 8-K | 5.02 | 0001725160-22-000170 | 001-39263 | 221271175 | 34 | 175806 | 1 | 1 |
| 2022-09-16 | 4 | FORM 4 | 0001725160-22-000167 | 10908 | ||||||
| 2022-09-12 | 4 | FORM 4 | 0001725160-22-000165 | 5039 | ||||||
| 2022-09-12 | 3 | FORM 3 | 0001725160-22-000164 | 476051 | ||||||
| 2022-09-12 | 8-K | 8-K | 5.02 | 0001725160-22-000163 | 001-39263 | 221237359 | 34 | 180863 | 1 | 1 |
| 2022-08-12 | 4 | FORM 4 | 0001725160-22-000159 | 6840 | ||||||
| 2022-08-09 | S-8 | S-8 | 0001725160-22-000157 | 333-266702 | 221148614 | 33 | 202228 | |||
| 2022-08-09 | 10-Q | 10-Q | 0001725160-22-000155 | 001-39263 | 221148449 | 34 | 6393023 | 1 | 1 | |
| 2022-08-09 | 8-K | 8-K | 2.02,7.01 | 0001725160-22-000154 | 001-39263 | 221148304 | 34 | 7335579 | 1 | 1 |
| 2022-08-01 | 4 | FORM 4 | 0001725160-22-000142 | 5794 | ||||||
| 2022-08-01 | 3 | FORM 3 | 0001725160-22-000141 | 391887 | ||||||
| 2022-07-22 | 8-K | 8-K | 5.02,9.01 | 0001725160-22-000138 | 001-39263 | 221100112 | 34 | 452307 | 1 | 1 |
| 2022-07-20 | 4 | FORM 4 | 0001725160-22-000135 | 6854 | ||||||
| 2022-07-14 | 4 | FORM 4 | 0001725160-22-000133 | 9355 | ||||||
| 2022-07-06 | 4 | FORM 4 | 0001725160-22-000131 | 7325 | ||||||
| 2022-06-29 | UPLOAD | filename1.pdf | 0000000000-22-006963 | 39801 | ||||||
| 2022-06-27 | 8-K | 8-K | 5.02 | 0001725160-22-000129 | 001-39263 | 221041573 | 34 | 176148 | 1 | 1 |
| 2022-06-22 | CORRESP | filename1.htm | 0001725160-22-000125 | 41835 | ||||||
| 2022-06-13 | 8-K | 8-K | 5.07 | 0001725160-22-000123 | 001-39263 | 221012361 | 34 | 195686 | 1 | 1 |
| 2022-06-10 | 4 | FORM 4 | 0001725160-22-000121 | 5105 | ||||||
| 2022-06-10 | 4 | FORM 4 | 0001725160-22-000120 | 5081 | ||||||
| 2022-06-09 | UPLOAD | filename1.pdf | 0000000000-22-006245 | 44798 | ||||||
| 2022-06-03 | 3 | xslF345X02/ownership.xml | 0000902664-22-003161 | 6766 | ||||||
| 2022-06-03 | SC 13D | ZENTALIS PHARMACEUTICALS, INC. | 0000902664-22-003160 | 005-91478 | 22993262 | 34 | 68112 | |||
| 2022-05-31 | 4 | FORM 4 | 0001725160-22-000116 | 7203 | ||||||
| 2022-05-31 | DEFA14A | DEFA14A | 0001725160-22-000115 | 001-39263 | 22983157 | 34 | 46688 | |||
| 2022-05-31 | 8-K | 8-K | 5.02,9.01 | 0001725160-22-000114 | 001-39263 | 22983151 | 34 | 336078 | 1 | 1 |
| 2022-05-26 | CORRESP | filename1.htm | 0001725160-22-000107 | 46867 | ||||||
| 2022-05-24 | 8-K | 8-K | 3.01 | 0001725160-22-000104 | 001-39263 | 22958170 | 34 | 178249 | 1 | 1 |
| 2022-05-20 | 4 | FORM 4 | 0001725160-22-000100 | 7787 | ||||||
| 2022-05-18 | DEFA14A | DEFA14A | 0001725160-22-000097 | 001-39263 | 22939045 | 34 | 50185 | |||
| 2022-05-16 | 8-K | 8-K | 8.01,9.01 | 0001628280-22-014546 | 001-39263 | 22930982 | 34 | 590376 | 1 | 1 |
| 2022-05-16 | 424B5 | 424B5 | 0001628280-22-014544 | 333-255769 | 22930955 | 33 | 485612 | |||
| 2022-05-16 | 8-K | FORM 8-K | 5.02,9.01 | 0001193125-22-150883 | 001-39263 | 22925452 | 34 | 339898 | 1 | 1 |
| 2022-05-12 | UPLOAD | filename1.pdf | 0000000000-22-005228 | 47610 | ||||||
| 2022-05-05 | 10-Q | 10-Q | 0001725160-22-000093 | 001-39263 | 22894012 | 34 | 5635190 | 1 | 1 | |
| 2022-05-05 | 8-K | 8-K | 2.02,9.01 | 0001725160-22-000092 | 001-39263 | 22893987 | 34 | 249126 | 1 | 1 |
| 2022-04-28 | DEFA14A | DEFA14A | 0001725160-22-000083 | 001-39263 | 22866776 | 34 | 291790 | |||
| 2022-04-28 | DEF 14A | DEF 14A | 0001725160-22-000082 | 001-39263 | 22866679 | 34 | 1045587 | |||
| 2022-04-27 | 424B5 | 424B5 | 0001628280-22-010798 | 333-255769 | 22859730 | 33 | 516701 | |||
| 2022-04-27 | 8-K | 8-K | 8.01,9.01 | 0001628280-22-010794 | 001-39263 | 22859615 | 34 | 497102 | 1 | 1 |
| 2022-04-13 | 4 | FORM 4 | 0001725160-22-000078 | 10916 | ||||||
| 2022-04-11 | 8-K | 8-K | 7.01,8.01,9.01 | 0001725160-22-000076 | 001-39263 | 22820113 | 34 | 214342 | 1 | 1 |
| 2022-04-11 | 8-K/A | 8-K | 7.01,9.01 | 0001725160-22-000075 | 001-39263 | 22820062 | 34 | 185055 | 1 | 1 |
| 2022-04-08 | 8-K | 8-K | 7.01,8.01 | 0001725160-22-000072 | 001-39263 | 22817782 | 34 | 8818989 | 1 | 1 |
| 2022-04-05 | 4 | FORM 4 | 0001725160-22-000069 | 12888 | ||||||
| 2022-04-05 | 4 | FORM 4 | 0001725160-22-000068 | 12509 | ||||||
| 2022-04-05 | 4 | FORM 4 | 0001725160-22-000067 | 10447 | ||||||
| 2022-03-21 | 4 | FORM 4 | 0001725160-22-000063 | 9355 | ||||||
| 2022-03-16 | 4 | FORM 4 | 0001725160-22-000061 | 8579 | ||||||
| 2022-03-10 | 4 | FORM 4 | 0001725160-22-000059 | 11387 | ||||||
| 2022-03-08 | 4 | FORM 4 | 0001725160-22-000057 | 7176 | ||||||
| 2022-03-03 | 4 | FORM 4 | 0001725160-22-000055 | 14844 | ||||||
| 2022-02-24 | 10-K | 10-K | 0001725160-22-000053 | 001-39263 | 22666498 | 34 | 15587097 | 1 | 1 | |
| 2022-02-24 | 8-K | 8-K | 2.02,9.01 | 0001725160-22-000052 | 001-39263 | 22666480 | 34 | 252464 | 1 | 1 |
| 2022-02-23 | 4 | FORM 4 | 0001725160-22-000048 | 13417 | ||||||
| 2022-02-23 | 4 | FORM 4 | 0001725160-22-000047 | 7280 | ||||||
| 2022-02-15 | 4 | FORM 4 | 0001725160-22-000038 | 9045 | ||||||
| 2022-02-14 | 4 | FORM 4 | 0001725160-22-000036 | 22554 | ||||||
| 2022-02-14 | 4 | FORM 4 | 0001725160-22-000035 | 11148 | ||||||
| 2022-02-14 | 4 | FORM 4 | 0001725160-22-000034 | 11126 | ||||||
| 2022-02-14 | 4 | FORM 4 | 0001725160-22-000033 | 7124 | ||||||
| 2022-02-14 | 4 | FORM 4 | 0001725160-22-000032 | 14763 | ||||||
| 2022-02-14 | 4 | FORM 4 | 0001725160-22-000031 | 15024 | ||||||
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001104659-22-023123 | 005-91478 | 22634485 | 34 | 68937 | |||
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001140361-22-005360 | 005-91478 | 22634212 | 34 | 279002 | |||
| 2022-02-14 | SC 13G | zntl13gdec21.txt | 0000080255-22-002228 | 005-91478 | 34 | 6968 | ||||
| 2022-02-14 | SC 13G | AMENDMENT NO. 1 | 0000929638-22-000451 | 005-91478 | 22627849 | 34 | 100262 | |||
| 2022-02-14 | SC 13G/A | ZENTALIS PHARMACEUTICALS, INC. | 0000902664-22-001676 | 005-91478 | 22627816 | 34 | 64204 | |||
| 2022-02-10 | SC 13G/A | SC 13G/A | 0001725160-22-000024 | 005-91478 | 22615190 | 34 | 45939 | |||
| 2022-02-10 | SC 13G/A | SCHEDULE 13G/A | 0001104659-22-018953 | 005-91478 | 22611269 | 34 | 13128 | |||
| 2022-02-09 | SC 13G/A | filing.txt | 0000315066-22-001263 | 005-91478 | 22604697 | 34 | 8626 | |||
| 2022-02-07 | 4 | FORM 4 | 0001725160-22-000019 | 9046 | ||||||
| 2022-02-03 | 4 | FORM 4 | 0001725160-22-000017 | 18117 | ||||||
| 2022-02-03 | SC 13G/A | us98943l1070_020322.txt | 0000834237-22-006439 | 005-91478 | 22589225 | 34 | 13552 | |||
| 2022-02-01 | SC 13G | d9169041_13-g.htm | 0000919574-22-000577 | 005-91478 | 22578643 | 34 | 166732 | |||
| 2022-01-20 | 4 | FORM 4 | 0001725160-22-000015 | 30805 | ||||||
| 2022-01-20 | 4 | FORM 4 | 0001725160-22-000014 | 11386 | ||||||
| 2022-01-19 | 4 | FORM 4 | 0001725160-22-000011 | 10914 | ||||||
| 2022-01-11 | 4 | FORM 4 | 0001725160-22-000009 | 14315 | ||||||
| 2022-01-05 | 4 | FORM 4 | 0001725160-22-000006 | 27579 | ||||||
| 2022-01-05 | 4 | FORM 4 | 0001725160-22-000005 | 8584 | ||||||
| 2022-01-05 | 4 | FORM 4 | 0001725160-22-000004 | 16093 | ||||||
| 2021-12-21 | 4 | FORM 4 | 0001725160-21-000244 | 13467 | ||||||
| 2021-12-17 | 4/A | FORM 4/A | 0001725160-21-000242 | 8184 | ||||||
| 2021-12-16 | 4 | FORM 4 | 0001725160-21-000240 | 18435 | ||||||
| 2021-12-13 | 4 | FORM 4 | 0001725160-21-000238 | 13462 | ||||||
| 2021-12-07 | 4/A | FORM 4/A | 0001725160-21-000236 | 6267 | ||||||
| 2021-12-07 | 4 | FORM 4 | 0001725160-21-000235 | 4889 | ||||||
| 2021-12-02 | 4 | FORM 4 | 0001725160-21-000232 | 37368 | ||||||
| 2021-12-02 | 4 | FORM 4 | 0001725160-21-000231 | 8588 | ||||||
| 2021-11-23 | 4 | FORM 4 | 0001725160-21-000228 | 6907 | ||||||
| 2021-11-17 | 8-K | 8-K | 8.01 | 0001725160-21-000226 | 001-39263 | 211421504 | 34 | 181955 | 1 | 1 |
| 2021-11-16 | 4 | FORM 4 | 0001725160-21-000224 | 9092 | ||||||
| 2021-11-12 | 4 | FORM 4 | 0001725160-21-000222 | 8736 | ||||||
| 2021-11-10 | 10-Q | 10-Q | 0001725160-21-000220 | 001-39263 | 211394460 | 34 | 13979179 | 1 | 1 | |
| 2021-11-10 | 8-K | 8-K | 2.02,9.01 | 0001725160-21-000219 | 001-39263 | 211394454 | 34 | 268932 | 1 | 1 |
| 2021-11-05 | 4 | FORM 4 | 0001725160-21-000213 | 9092 | ||||||
| 2021-11-02 | 4 | FORM 4 | 0001725160-21-000211 | 19238 | ||||||
| 2021-11-02 | 4 | FORM 4 | 0001725160-21-000210 | 8588 | ||||||
| 2021-10-27 | 4 | FORM 4 | 0001725160-21-000207 | 8592 | ||||||
| 2021-10-27 | 4 | FORM 4 | 0001725160-21-000206 | 14461 | ||||||
| 2021-10-04 | 4 | FORM 4 | 0001725160-21-000201 | 10961 | ||||||
| 2021-10-04 | 4 | FORM 4 | 0001725160-21-000200 | 15807 | ||||||
| 2021-10-04 | 4 | FORM 4 | 0001725160-21-000199 | 4906 | ||||||
| 2021-10-04 | 4 | FORM 4 | 0001725160-21-000198 | 11294 | ||||||
| 2021-10-04 | 4 | FORM 4 | 0001725160-21-000197 | 8667 | ||||||
| 2021-09-02 | 4 | FORM 4 | 0001725160-21-000191 | 7224 | ||||||
| 2021-09-02 | 4 | FORM 4 | 0001725160-21-000190 | 11762 | ||||||
| 2021-09-02 | 4 | FORM 4 | 0001725160-21-000189 | 10726 | ||||||
| 2021-08-20 | 4 | FORM 4 | 0001725160-21-000185 | 7016 | ||||||
| 2021-08-12 | 10-Q | 10-Q | 0001725160-21-000183 | 001-39263 | 211165523 | 34 | 7291882 | 1 | 1 | |
| 2021-08-12 | 8-K | 8-K | 2.02 | 0001725160-21-000181 | 001-39263 | 211165517 | 34 | 269968 | 1 | 1 |
| 2021-08-03 | 4 | FORM 4 | 0001725160-21-000176 | 19238 | ||||||
| 2021-08-03 | 4 | FORM 4 | 0001725160-21-000175 | 12761 | ||||||
| 2021-08-03 | 4 | FORM 4 | 0001725160-21-000174 | 10961 | ||||||
| 2021-07-08 | 4 | FORM 4 | 0001725160-21-000170 | 17451 | ||||||
| 2021-07-08 | 4 | FORM 4 | 0001725160-21-000169 | 20070 |
One latest value per concept from companyfacts (293 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 98.27M | 2026-11-04 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 66.90M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 212,506 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001725160-26-000027 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 1.44M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001725160-26-000027 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 7 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-30 | 0001725160-26-000027 | ||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 5.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 423,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | AccruedIncomeTaxesCurrent | Accrued Income Taxes, Current | USD | 175,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AccruedLiabilitiesAndOtherLiabilities | Accrued Liabilities and Other Liabilities | USD | 27.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 27.03M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 359,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 3.22M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -495,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 1.50B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 9.63M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 9.63M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | AllowanceForDoubtfulAccountsReceivable | Accounts Receivable, Allowance for Credit Loss | USD | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001725160-21-000075 | |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 18.32M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | AssetAcquisitionContingentConsiderationLiability | AssetAcquisitionContingentConsiderationLiability | USD | 500,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AssetAcquisitionContingentConsiderationLiabilityCurrent | AssetAcquisitionContingentConsiderationLiabilityCurrent | USD | 500,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AssetImpairmentCharges | Asset Impairment Charges | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | Assets | Assets | USD | 270.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 237.27M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 214.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 495,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 205.36M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss | USD | 15,000 | 2020-06-30 | 2020 | Q2 | 10-Q | 2020-08-13 | 0001725160-20-000016 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | USD | 27.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value | USD | 204.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 204.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 204.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0001725160-24-000080 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 24.03M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | CashAndCashEquivalentsFairValueDisclosure | Cash and Cash Equivalents, Fair Value Disclosure | USD | 9.60M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 26.66M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -11.97M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | CashDivestedFromDeconsolidation | Cash Divested from Deconsolidation | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0001725160-24-000080 |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 250.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 98.26M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 98.26M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 98,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -107.14M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | USD | -137.42M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | CurrentForeignTaxExpenseBenefit | Current Foreign Tax Expense (Benefit) | USD | 63,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | 391,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 328,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | USD | 0 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-09 | 0001725160-22-000155 |
| us-gaap | DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | USD | 4,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | security | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | USD | 495,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions | security | 32 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedLossPosition | Debt Securities, Available-for-sale, Unrealized Loss Position | USD | 495,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions | Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | security | 32 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | DeconsolidationGainOrLossAmount | Deconsolidation, Gain (Loss), Amount | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | DeferredCosts | Deferred Costs, Noncurrent | USD | 716,000 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-12 | 0001725160-21-000183 | |
| us-gaap | DeferredFederalIncomeTaxExpenseBenefit | Deferred Federal Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | DeferredForeignIncomeTaxExpenseBenefit | Deferred Foreign Income Tax Expense (Benefit) | USD | 51,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | DeferredIncomeTaxAssetsNet | Deferred Income Tax Assets, Net | USD | 51,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | DeferredIncomeTaxesAndTaxCredits | Deferred Income Taxes and Tax Credits | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | 51,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 7.61M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredIncomeTaxLiabilitiesNet | Deferred Income Tax Liabilities, Net | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0001725160-24-000080 | |
| us-gaap | DeferredStateAndLocalIncomeTaxExpenseBenefit | Deferred State and Local Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | DeferredTaxAssetsGoodwillAndIntangibleAssets | Deferred Tax Assets, Goodwill and Intangible Assets | USD | 9.45M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 289.64M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsInProcessResearchAndDevelopment | Deferred Tax Assets, in Process Research and Development | USD | 72.12M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 51,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 7.67M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 145.81M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 28,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 41.55M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation | USD | 1.90M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 9.07M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | USD | 322,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001725160-25-000067 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses | USD | 2.50M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 281.98M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 853,000 | 2022-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0001725160-24-000080 | |
| us-gaap | DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 | |
| us-gaap | DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates | Deferred Tax Liabilities, Investment in Noncontrolled Affiliates | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001725160-25-000067 | |
| us-gaap | DeferredTaxLiabilitiesLeasingArrangements | Deferred Tax Liabilities, Leasing Arrangements | USD | 6.45M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxLiabilitiesOther | Deferred Tax Liabilities, Other | USD | 675,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DeferredTaxLiabilitiesPropertyPlantAndEquipment | Deferred Tax Liabilities, Property, Plant and Equipment | USD | 487,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | DefinedContributionPlanCostRecognized | Defined Contribution Plan, Cost | USD | 1.40M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 456,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | DueFromRelatedPartiesCurrent | Due from Related Parties, Current | USD | 7.91M | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-10 | 0001725160-23-000113 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -1.41 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -1.24 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-17 | 0001725160-21-000129 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -1.41 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | -0.003 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.193 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | 0 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount | USD | -44,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent | pure | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.008 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.037 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | -0.002 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount | USD | 11.29M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent | pure | -0.068 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | -0.002 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.027 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 7.39M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | EquityMethodInvestments | Equity Method Investments | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001725160-25-000067 | |
| us-gaap | EquitySecuritiesFvNi | Equity Securities, FV-NI | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | EquitySecuritiesFvNiCurrentAndNoncurrent | EquitySecuritiesFvNiCurrentAndNoncurrent | USD | 19.17M | 2024-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | EquitySecuritiesFvNiGainLoss | Equity Securities, FV-NI, Gain (Loss) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | EquitySecuritiesFvNiRealizedGainLoss | Equity Securities, FV-NI, Realized Gain (Loss) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | EquitySecuritiesFvNiUnrealizedGainLoss | Equity Securities, FV-NI, Unrealized Gain (Loss) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | FiniteLivedIntangibleAssetsNet | Finite-Lived Intangible Assets, Net | USD | 0 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-10 | 0001725160-21-000220 | |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 27.19M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | Goodwill | Goodwill | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001725160-25-000067 | |
| us-gaap | GoodwillImpairmentLoss | Goodwill, Impairment Loss | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue | Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | USD | 176.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | ImpairmentOfIntangibleAssetsExcludingGoodwill | Impairment of Intangible Assets (Excluding Goodwill) | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0001725160-24-000080 |
| us-gaap | ImpairmentOfIntangibleAssetsFinitelived | Impairment of Intangible Assets, Finite-lived | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -136.99M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -106.08M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | 368,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | USD | -136.62M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeLossFromEquityMethodInvestments | Income (Loss) from Equity Method Investments | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxesPaid | Income Taxes Paid | USD | 85,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 85,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 376,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | IncomeTaxPaidFederalAfterRefundReceived | IncomeTaxPaidFederalAfterRefundReceived | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxPaidForeignAfterRefundReceived | IncomeTaxPaidForeignAfterRefundReceived | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 26.37M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount | USD | 0 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | USD | -1,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -28.69M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 1.14M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 5.05M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | 320,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 261,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 3.64M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncreaseDecreaseInAccountsPayableAndAccruedLiabilities | Increase (Decrease) in Accounts Payable and Accrued Liabilities | USD | -4.59M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | -5.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | IncreaseDecreaseInDeferredIncomeTaxes | Increase (Decrease) in Deferred Income Taxes | USD | 769,000 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 1.09M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | IncreaseDecreaseInReceivables | Increase (Decrease) in Receivables | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | IncrementalCommonSharesAttributableToShareBasedPaymentArrangements | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements | shares | 294,000 | 2024-01-01 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-07 | 0001725160-24-000107 |
| us-gaap | IndefiniteLivedIntangibleAssetsExcludingGoodwill | Indefinite-lived Intangible Assets (Excluding Goodwill) | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 | |
| us-gaap | InterestReceivable | Interest Receivable | USD | 2.29M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | InterestReceivableCurrent | Interest Receivable, Current | USD | 511,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-09 | 0001725160-20-000034 | |
| us-gaap | InvestmentIncomeAmortizationOfPremium | Investment Income, Amortization of Premium | USD | 17,000 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-09 | 0001725160-22-000155 |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 313,000 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-10 | 0001725160-21-000220 |
| us-gaap | Investments | Investments | USD | 349.93M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-12 | 0001725160-24-000173 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 48.05M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 14.98M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 7.45M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 8.11M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 8.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 7.93M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 7.76M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 1.82M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 11.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths | Lessor, Operating Lease, Payment to be Received, Year One | USD | 655,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | Liabilities | Liabilities | USD | 65.31M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 270.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 32.36M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LiabilitiesFairValueDisclosure | Financial and Nonfinancial Liabilities, Fair Value Disclosure | USD | 500,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest | Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest | USD | 434.02M | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 | |
| us-gaap | MembersEquity | Members' Equity | USD | 433.80M | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 | |
| us-gaap | MembersEquityAttributableToNoncontrollingInterest | Members' Equity Attributable to Noncontrolling Interest | USD | 221,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 | |
| us-gaap | MinorityInterest | Stockholders' Equity Attributable to Noncontrolling Interest | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001725160-25-000067 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 86.20M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 4.73M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -102.90M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -106.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | NetIncomeLossAttributableToNoncontrollingInterest | Net Income (Loss) Attributable to Noncontrolling Interest | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | NoncontrollingInterestDecreaseFromDeconsolidation | Noncontrolling Interest, Decrease from Deconsolidation | USD | 79,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance | Noncontrolling Interest, Increase from Subsidiary Equity Issuance | USD | 18.42M | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 113.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -113.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 6.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | OperatingLeaseImpairmentLoss | Operating Lease, Impairment Loss | USD | 3.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 36.71M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 4.27M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 32.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 6.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 23.83M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.09 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 669,000 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 | |
| us-gaap | OtherAssetImpairmentCharges | Other Asset Impairment Charges | USD | 4.14M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | USD | -691,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | USD | 0 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-09 | 0001725160-22-000200 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | 14,000 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-17 | 0001725160-21-000129 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | USD | -691,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 500,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | OtherNonoperatingExpense | Other Nonoperating Expense | USD | 44,000 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-17 | 0001725160-21-000129 |
| us-gaap | OtherReceivables | Other Receivables | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0001725160-24-000080 | |
| us-gaap | PaymentsForRepurchaseOfCommonStock | Payments for Repurchase of Common Stock | USD | 9.98M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | PaymentsForRestructuring | Payments for Restructuring | USD | 6.99M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | PaymentsOfFinancingCosts | Payments of Financing Costs | USD | 0 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-09 | 0001725160-22-000155 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 5.70M | 2026-08-17 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PaymentsToAcquireAvailableForSaleSecuritiesDebt | Payments to Acquire Debt Securities, Available-for-sale | USD | 175.23M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 34,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PrepaidExpenseAndOtherAssets | Prepaid Expense and Other Assets | USD | 12.49M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 8.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PrepaidExpenseAndOtherAssetsNoncurrent | Prepaid Expense and Other Assets, Noncurrent | USD | 4.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 578,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 86.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock | Proceeds from Issuance of Redeemable Convertible Preferred Stock | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised | USD | 707,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | USD | 180.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | ProceedsFromMinorityShareholders | Proceeds from Noncontrolling Interests | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | ProceedsFromSaleOfEquitySecuritiesFvNi | ProceedsFromSaleOfEquitySecuritiesFvNi | USD | 20.41M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | ProceedsFromSaleOfPropertyPlantAndEquipment | Proceeds from Sale of Property, Plant, and Equipment | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 8,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001725160-25-000067 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -137.06M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 5.57M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 2.35M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | ReclassificationsOfTemporaryToPermanentEquity | Reclassifications of Temporary to Permanent Equity | USD | 155.93M | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-03-01 | 0001725160-23-000048 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 86.21M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 2.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-02-27 | 0001725160-24-000080 | |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 2.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | RestrictedStockValueSharesIssuedNetOfTaxWithholdings | Restricted Stock, Value, Shares Issued Net of Tax Withholdings | USD | -1.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | RestructuringAndRelatedCostIncurredCost | Restructuring and Related Cost, Incurred Cost | USD | 6.99M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent | pure | 0.4 | 2025-01-28 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | RestructuringCharges | Restructuring Charges | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | RestructuringReserve | Restructuring Reserve | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | RestructuringReserveCurrent | Restructuring Reserve, Current | USD | 87,000 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-10 | 0001725160-25-000161 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -1.30B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | SaleOfStockNumberOfSharesIssuedInTransaction | Sale of Stock, Number of Shares Issued in Transaction | shares | 26.45M | 2026-08-17 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | SaleOfStockPricePerShare | Sale of Stock, Price Per Share | USD/shares | 3.5 | 2026-08-17 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 9.63M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 5.87M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 17.52 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001725160-25-000067 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 3.59M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 2.48M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 15.11 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-09 | 0001725160-20-000034 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 16,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 12.26M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 11.02 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 16,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 12.26M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 11.02 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value | USD/shares | 0.94 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 21.17 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 1.64 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | SharePrice | Share Price | USD/shares | 1.4 | 2025-12-12 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 204.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | USD | 204.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited | Stock Issued During Period, Shares, Restricted Stock Award, Forfeited | shares | 1,000 | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-12 | 0001725160-21-000183 |
| us-gaap | StockIssuedDuringPeriodSharesRestrictedStockAwardGross | Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares | 1.14M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 68,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfUnits | Stock Issued During Period, Value, Conversion of Units | USD | 0 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 581,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 86.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardGross | Stock Issued During Period, Value, Restricted Stock Award, Gross | USD | 1,000 | 2022-01-01 | 2022-09-30 | 2023 | Q3 | 10-Q | 2023-11-06 | 0001725160-23-000196 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 126,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | StockRepurchasedDuringPeriodValue | Stock Repurchased During Period, Value | USD | 9.98M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | SubleaseIncome | Sublease Income | USD | 1.10M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | TemporaryEquityAggregateAmountOfRedemptionRequirement | Temporary Equity, Aggregate Amount of Redemption Requirement | USD | 146.94M | 2019-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001725160-21-000075 | |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 155.93M | 2020-03-31 | 2021 | Q1 | 10-Q | 2021-05-17 | 0001725160-21-000129 | |
| us-gaap | TemporaryEquityLiquidationPreference | Temporary Equity, Liquidation Preference | USD | 146.94M | 2019-12-31 | 2020 | FY | 10-K | 2021-03-25 | 0001725160-21-000075 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 | |
| us-gaap | TemporaryEquitySharesIssued | Temporary Equity, Shares Issued | shares | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 | |
| us-gaap | TemporaryEquitySharesOutstanding | Temporary Equity, Shares Outstanding | shares | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-02-24 | 0001725160-22-000053 | |
| us-gaap | TemporaryEquityStockIssuedDuringPeriodValueNewIssues | Temporary Equity, Stock Issued During Period, Value, New Issues | USD | 14.23M | 2020-01-01 | 2020-06-30 | 2021 | Q2 | 10-Q | 2021-08-12 | 0001725160-21-000183 |
| us-gaap | TradingSecuritiesDebt | Debt Securities, Trading | USD | 204.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 16.03M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 | |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 827,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 392,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 35.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-26 | 0001725160-26-000014 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 75.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 40.36M | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-17 | 0001725160-21-000129 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 75.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001725160-26-000070 |